With the increasing expansion of the biopharmaceutical industry, many manufacturers are facing multiple problems like dearth of expertise and systematic equipment during in-house manufacturing. The availability of external funding and biotech manufacturing has led to a spurt of bio companies in early stage as they are the primary CMO customers due to their lack of capability of developing vigorous manufacturing operations. Multiple established CMOs like Lonza and Boehringer Ingelheim have received competition from many emerging CMOs in this high-volume market. For example, Samsung entered this market as Samsung Biologics in 2013 and has since expanded their bioreactor capacities to witness growth in this sector. The company currently owns three plants with over 360,000 litres of capacity and the fourth plant is under assessment, which shall be located outside South Korea. Additionally, technological breakthroughs in bioprocessing have been crucial in the development of CMOs by working on issues like need of a batch-wise changeover and high production costs. Bioprocessing systems that can use once have proven to be significant in reducing the total scale-up and production costs. With strategic acquisitions and mergers, the biopharmaceutical contract manufacturing market growth is expected to grow substantially over the forecasted timeframe. However, established companies consider outsourcing as unfeasible owing to limited management oversight and loss of strategic control, resulting in these companies choosing in-house manufacturing operations.